Zymeworks (ZYME) closed at $28.45 on October 22, 2026, up 1.2% from the previous close, on volume of 700,470 shares (30-day average 1,151,120).
Data as of October 22, 2026.
Globe Newswire (Mon, 19-Oct 6:00 AM ET)
Globe Newswire (Thu, 15-Oct 6:00 AM ET)
Globe Newswire (Mon, 28-Sep 6:00 AM ET)
Zymeworks Completes Acquisition of Theravance Biopharma
Globe Newswire (Wed, 23-Sep 4:01 PM ET)
Globe Newswire (Tue, 25-Aug 10:23 AM ET)
Zymeworks Announces Participation in Upcoming Investor Conferences
Globe Newswire (Tue, 11-Aug 6:00 AM ET)
Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Globe Newswire (Thu, 6-Aug 4:05 PM ET)
Zymeworks Highlights Promising Zanidatamab Data Across HER2+ Cancers at Upcoming AACR Meeting
Market Chameleon (Wed, 18-Mar 3:53 AM ET)
Zymeworks’ Phase 3 Results Point to Ziihera as Potential New Standard of Care in HER2-Positive GEA
Market Chameleon (Mon, 17-Nov 5:31 AM ET)
Ziihera Achieves Landmark Phase 3 Results, Paving Way for New HER2-Positive GEA Treatment Standard
Market Chameleon (Mon, 17-Nov 2:06 AM ET)
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Zymeworks trades on the NASDAQ stock market under the symbol ZYME.
As of October 22, 2026, ZYME stock price climbed to $28.45 with 700,470 million shares trading.
ZYME has a beta of 0.36, meaning it tends to be less sensitive to market movements. ZYME has a correlation of 0.01 to the broad based SPY ETF.
ZYME has a market cap of $2.04 billion. This is considered a Mid Cap stock.
Last quarter Zymeworks reported $5 million in Revenue and -$.62 earnings per share. This fell short of revenue expectation by $-14 million and missed earnings estimates by -$.22.
In the last 3 years, ZYME traded as high as $31.34 and as low as $6.51.
The top ETF exchange traded funds that ZYME belongs to (by Net Assets): VTI, IWM, IBB, IWO, DFAS.
ZYME has outperformed the market in the last year with a price return of +58.7% while the SPY ETF gained +14.9%. ZYME has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +18.3% and +7.2%, respectively, while the SPY returned +2.3% and -1.7%, respectively.
ZYME support price is $27.26 and resistance is $28.97 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ZYME shares will trade within this expected range on the day.